Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia

Summary

The purpose of this study is to determine whether PRX302 is safe and effective in the treatment of moderate to severe Benign Prostatic Hyperplasia (BPH).

Timeline

Start

2009-01

Primary completion

2009-12

Completion

2010-09

Outcome

Met primary endpoint

registry MEAN PRX302: -9.1 (Standard Deviation 5.95) score MEAN Placebo: -5.8 (Standard Deviation 5.40) score analysis (superiority or other test); PRX302 vs Placebo; p = 0.040 NCT00889707 ↗

Drugs

Indications